![Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis | Neurodegenerative Disease Management Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis | Neurodegenerative Disease Management](https://www.futuremedicine.com/cms/10.2217/nmt-2022-0014/asset/images/medium/figure1.gif)
Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis | Neurodegenerative Disease Management
![Study: Short-Term Use of Prescription Medication Containing THC and CBD Not Associated with Cardiovascular Complications in High-Risk Patients - NORML Study: Short-Term Use of Prescription Medication Containing THC and CBD Not Associated with Cardiovascular Complications in High-Risk Patients - NORML](https://i0.wp.com/norml.org/wp-content/uploads/2022/03/sativex-spray.jpg?fit=730%2C411&ssl=1)
Study: Short-Term Use of Prescription Medication Containing THC and CBD Not Associated with Cardiovascular Complications in High-Risk Patients - NORML
![A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01259-3/MediaObjects/41416_2021_1259_Fig1_HTML.png)
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | British Journal of Cancer
![Il Sativex sclerosi multipla di farmaco. Il Sativex è un oromucosal cannabinoide bocca spray sviluppato dalla GW Pharmaceuticals per i pazienti con sclerosi multipla. Ho Foto stock - Alamy Il Sativex sclerosi multipla di farmaco. Il Sativex è un oromucosal cannabinoide bocca spray sviluppato dalla GW Pharmaceuticals per i pazienti con sclerosi multipla. Ho Foto stock - Alamy](https://c8.alamy.com/compit/2ackgt7/il-sativex-sclerosi-multipla-di-farmaco-il-sativex-e-un-oromucosal-cannabinoide-bocca-spray-sviluppato-dalla-gw-pharmaceuticals-per-i-pazienti-con-sclerosi-multipla-ho-2ackgt7.jpg)
Il Sativex sclerosi multipla di farmaco. Il Sativex è un oromucosal cannabinoide bocca spray sviluppato dalla GW Pharmaceuticals per i pazienti con sclerosi multipla. Ho Foto stock - Alamy
![Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity : the Belgian experience Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity : the Belgian experience](https://biblio.ugent.be/publication/01GVZB2V55PGXR14NPF52MNEMT/file/01GVZB3VT34F6KY4FZ2TZ6WW3N/thumbnail.png)